Gastrointestinal safety across the albiglutide development programme
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Gastrointestinal (GI) adverse events (AEs) are the most frequently reported treatment‐related AEs associated with glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in the treatment of type 2 diabetes mellitus. The GI safety of albiglutide, a once‐weekly GLP‐1RA, was assessed using data from five phase III studies. In a pooled analysis of four placebo‐controlled trials, the most common GI AEs were diarrhoea (albiglutide, 14.5% vs. placebo, 11.5%) and nausea (albiglutide, 11.9% vs. placebo, 10.3%), with most patients experiencing 1–2 events. The majority were mild or moderate in intensity and their median duration was 3–4 days. Vomiting occurred in 4.9% of patients in the albiglutide vs. 2.6% in the placebo group. For both albiglutide and placebo, serious GI AEs (2.0% vs. 1.5%) and withdrawals attributable to GI AEs (1.7% vs. 1.5%) were low. In a 32‐week trial of albiglutide 50 mg weekly versus liraglutide 1.8 mg daily, nausea occurred in 9.9% of patients in the albiglutide group vs. 29.2% in the liraglutide group. Vomiting occurred in 5.0% in the albiglutide vs. 9.3% in the liraglutide group. In conclusion, albiglutide has an acceptable GI tolerability profile, with nausea and vomiting rates slightly higher than those for placebo but lower than those for liraglutide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) provide effective glucose-lowering in type 2 diabetes mellitus (T2DM) and are associated with beneficial effects on body weight and blood pressure [1,2].”
BackgroundPratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326 · cited 9×
“Rates of nausea and vomiting on initiation of albiglutide treatment were initially lower and generally stable from week 1 through to the end of study, and no clinically relevant change was seen when the albiglutide dose was increased to 50 mg [12].”
BackgroundMethodResultInfluential
Cited by
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
Zhang, Z., Zhang, Q., Tan, Y., Chen, Y., Zhou, X., Liu, S., & Yu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149328 · Cited by 46
“A meta-analysis of GI AEs, mainly based on the HARMONY series of trials, showed that the GI tolerability of albiglutide was lower than that of liraglutide, while the numbers of included literature were small, and the results were too single (6); Lin Xia et al.”
ResultCorrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
Borner, T., Workinger, J. L., Tinsley, I. C., Fortin, S. M., Stein, L. M., Chepurny, O. G., Holz, G. G., Wierzba, A. J., Gryko, D., Nexø, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107768 · Cited by 39
Shaddinger, B. C., Young, M. A., Billiard, J., Collins, D. A., Hussaini, A., & Nino, A. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.940 · Cited by 22
Metadata
- Authors
- Leiter, L. A., Mallory, J. M., Wilson, T. H., & Reinhardt, R. R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-05-31
- Volume
- 18
- Issue
- 9
- Pages
- 930-935
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2341277771
- Cited by
- 13
- References
- 2
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastrointestinal safety across the albiglutide development programme. https://app.cochat.ai/papers/10.1111/dom.12679
- The paper
- Leiter, L. A., Mallory, J. M., Wilson, T. H., & Reinhardt, R. R. (2016). Gastrointestinal safety across the albiglutide development programme. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12679
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.